What is Henry Schein's stock symbol?
Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."
Where is Henry Schein's stock going? Where will Henry Schein's stock price be in 2017?
10 brokerages have issued 12-month target prices for Henry Schein's stock. Their forecasts range from $163.00 to $208.00. On average, they expect Henry Schein's share price to reach $181.88 in the next year.
When will Henry Schein announce their earnings?
Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Henry Schein stock?
Here are some recent quotes from research analysts about Henry Schein stock:
- Evercore ISI analysts commented, "HSIC continues to deliver consistent HSD to LDD EPS growth despite an operating environment that has been somewhat mixed, albeit North American Dental continues to show signs of recovery. With the acquisition engine still churning and an elevated level of buybacks, management has been able to deliver the type of TSR expected and thus the valuation remains notably elevated on an absolute basis (less so on a relative basis). While we also value consistency and predictability, we acknowledge we missed the November entry point (fears of US slowdown) and thus at current levels see risk / reward as more fully balanced (particularly with extra week headwind in 2017 + unfavorable Fx environment). Given this dynamic we reiterate our Hold rating and argue shares are now accurately pricing in the current operating environment. Thus we await another period of uncertainty prior to revisiting our long-term constructive view on shares." (2/21/2017)
According to Zacks Investment Research, "In the last three months, Henry Schein’s share price trend witnessed a neck and neck movement with the broader Medical product market trend. However the trend surpassed the latter on posting third quarter 2016 earnings. The results were mixed with earnings beating the Zacks Consensus Estimate and revenues meeting the mark. Also the company’s strong share gains in both North American and overseas markets raise optimism. We also keenly await Henry Schein’s impending acquisition of Marrodent which should help the former to capture the bountiful dental market opportunities in Poland. Despite each segment’s strong sales growth, the company’s unchanged EPS guidance for 2016 was disappointing. The year-over-year decline in Henry Schein’s gross and operating margin due to higher cost of sales and expenses also concerns us. Meanwhile, foreign currency fluctuations continued to hamper the company’s business." (1/9/2017)
Who owns Henry Schein stock?
Henry Schein's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.98%), State Street Corp (4.51%), Janus Capital Management LLC (2.72%), Atlanta Capital Management Co. L L C (1.82%), Franklin Resources Inc. (0.69%) and Renaissance Technologies LLC (0.59%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, James P Breslawski, Kurt P Kuehn, Leonard A David, Lonnie Shoff, Louis W Sullivan, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Norman S Matthews, Paul Brons, Paul Rose, Peter M Mccarthy, Philip A Laskawy, Robert Minowitz, Stanley Komaroff, Stanley M Bergman and Steven Paladino.
Who sold Henry Schein stock? Who is selling Henry Schein stock?
Henry Schein's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Aviva PLC, Fiera Capital Corp, Martingale Asset Management L P, Comerica Bank, AQR Capital Management LLC, Ativo Capital Management LLC and Credit Agricole S A. Company insiders that have sold Henry Schein stock in the last year include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lonnie Shoff, Louis W Sullivan, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Norman S Matthews, Paul Brons, Peter M Mccarthy, Philip A Laskawy and Robert Minowitz.
Who bought Henry Schein stock? Who is buying Henry Schein stock?
Henry Schein's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Congress Asset Management Co. MA, Champlain Investment Partners LLC, Atlanta Capital Management Co. L L C, Asset Management One Co. Ltd., AMF Pensionsforsakring AB, Russell Investments Group Ltd. and Bluestein R H & Co..
How do I buy Henry Schein stock?
Shares of Henry Schein can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Henry Schein stock cost?
One share of Henry Schein stock can currently be purchased for approximately $172.64.